Dublin, July 03, 2019 (GLOBE NEWSWIRE) -- The "Cemiplimab" report has been added to ResearchAndMarkets.com's offering.
Cemiplimab (Regeneron/Sanofi) is a programmed death-1 (PD-1)-targeted monoclonal antibody. The interaction between PD-1 and its ligand PD-L1 on a T cell reduces T-cell function signals, resulting in tumor cell survival and proliferation due to immune system suppression. The disruption of this interaction reduces the ability of the tumor to evade immune system targeting and enhances antitumor immune responses.
Key Topics Covered
List of Figures
Figure 1: The authors drug assessment summary for Tagrisso in non-small cell lung cancer
Figure 2: The authors drug assessment summary for Imfinzi in non-small cell lung cancer
List of Tables
Table 1: Cemiplimab drug profile
Table 2: Cemiplimab Phase III trials in non-small cell lung cancer
Table 3: Cemiplimab early-phase data in non-small cell lung cancer
Table 4: Cemiplimab sales for NSCLC across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 5: Cemiplimab patient numbers for NSCLC across the US, Japan, and five major EU markets, by country, 2017-26
Table 6: Gilotrif patient numbers for NSCLC across the US, Japan, and five major EU markets, by country, 2017-26
For more information about this report visit https://www.researchandmarkets.com/r/1g5zdp
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager email@example.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 Related Topics: Oncology Drugs